SBIR and STTR Success Story for
Vital Art and Science Incorporated

(Information Posted/Updated on 06/13/2013)

Vital Art and Science Incorporated
2725 N. Spring Dr.
Richardson, TX  75082-4233

Contact:    Mike Bartlett
Phone:      214-989-7130
Web Site:

Project Title:  myVisionTrack™ Home Vision Monitor
Related Award(s):  1R43EY020016
Technology Developed:
A Shape Discrimination Hyper-Acuity (SDH) algorythm developed at the Retina Foundation of the Southwest was licensed and then modified for delivery on the Apple iPhone and iPad. This was then extensively tested in both cross-sectional and longitudinal Studies which showed that the home test results were highly correlated with traditional administered Snellen Chart testing in the clinic, and that even elderly patients with impaired vision could and would accurately test their own vision at home. The commercial version provides automatic uploading for monitoring and notification of the physician when a significant change in vision is detected.

Key Words:  Vision Monitor, in-home monitoring, SDH, wet AMD, diabetic retinopathy.
Uses of Technology/Products/Service:
"myVisionTrack™ will extend vision care into the home and has application in at least 4 important areas: 1) Patient monitoring during active treatment for detection of visual changes for re-treatment; 2) Monitoring of 'at risk' patients for significant changes indicating disease activity and a need for treatment; 3) In Ophthalmic Drug Trials to collect much more data at very low cost, which will both reduce the cost and time of traditional trials and help improve clinical outcomes and facilitate regulatory approvals; and 4) We hope to demonstrate in the near future that myVisionTrack™ is effective for general use in large-scale vision screening and early detection of disease onset."

Benefit to Company:
The SBIR Phase I and Phase II funding was crucial to the development and validation of myVisionTrack™. The SBIR funding directly funded our early development and Proof-of-Concept Clinical Study which demonstrated that elderly patients with retinal disease were capable of self-testing their vision, and that the results were highly correlated with administered vision testing in the clinic. Besides providing funding that we could not get anywhere else for early development, the SBIR grants also got us significant recognition. Immediately after receiving our Phase I Award we were contacted by a large Drug Company who was interested in our work, which had been approved for NEI Award, and they ultimately funded a large Clinical Trial which provided independent validation of myVisionTrack™.

How Product Was Commercialized:
The myVisionTrack™ Model 0003 (iPhone version) received FDA 510(k) clearance (K121738) on Feb. 22, 2013. We are in discussions and expect to license myVisionTrack™ for use in Clinical Drug Trials and for use as a Companion Diagnostic to complement existing ophthalmic drugs.

Other Comments Related to Company's Success Story:
The NIH SBIR funding enabled us to help clinically validate and achieve the first FDA 510k cleared, low cost, easy to use in-home diagnostic device that is highly correlated with visual acuity.

Past R&D and/or Sales from this Project:   $950,000
Estimated Future Annual R&D and/or Sales from this Project:   $5,000,000